Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Merck Serono has teamed up with Bristol-Myers Squibb to co-promote the Glucophage diabetes brand in China.
The deal will involve a number of different formulations of Glucophage (metformin), which is a mainstay of type II diabetes treatment and, in its original form, widely available as a generic.
China is estimated to have more people with diabetes than any other country with more than 90 million thought to be living with the condition. Eyeing this potential patient population, Merck KGaA's biopharmaceutical division is keen to expand its position in the market.
Belen Garijo, chief operating officer of the company's Merck Serono division, said: ?The incidence of type II diabetes in China is growing at a tremendous rate. This new collaboration will help ensure that we continue to be a leading solution provider for these patients.
http://www.pmlive.com/pharma_news/merck_serono_signs_diabetes_partnership_with_bms_in_china_468347
The deal will involve a number of different formulations of Glucophage (metformin), which is a mainstay of type II diabetes treatment and, in its original form, widely available as a generic.
China is estimated to have more people with diabetes than any other country with more than 90 million thought to be living with the condition. Eyeing this potential patient population, Merck KGaA's biopharmaceutical division is keen to expand its position in the market.
Belen Garijo, chief operating officer of the company's Merck Serono division, said: ?The incidence of type II diabetes in China is growing at a tremendous rate. This new collaboration will help ensure that we continue to be a leading solution provider for these patients.
http://www.pmlive.com/pharma_news/merck_serono_signs_diabetes_partnership_with_bms_in_china_468347